Renal Anemia Treatment in the Us- How Payer Policies and Physician Preferences Drive Prescribing and How will the Emerging Oral HIF-PH Inhibitors Influence Payers and Physicians?

作者：Jk Khan, Ellen O’Connor, R Moore, Cameron Lewis, M Fletcher-Louis · 发表于：Value in Health · 年份：2016 · DOI：10.1016/j.jval.2016.09.1009 · 被引用次数：1 · 研究领域：Erythropoietin and Anemia Treatment、Organ Donation and Transplantation